Experienced Manufacturing Lannett's extensive history since 1942 and its large-scale production capabilities, including 3.5 billion oral solid doses and 2 million liters of liquid pharmaceuticals annually, position it as a reliable partner for high-volume medication manufacturing and custom formulation projects.

Strategic Industry Positioning As a long-established CDMO with recent developments in biosimilars and generic drugs, Lannett is actively expanding its portfolio and technological capabilities, presenting opportunities for partnerships in biosimilar development and specialty pharmaceuticals.

Recent Acquisition Interest The potential acquisition by Aurobindo Pharma for $250M indicates strong market interest and valuation, suggesting growth opportunities for suppliers who can align with Lannett’s evolving corporate strategy and expansion plans.

Product Launch & Innovation Lannett’s recent launch of generic and biosimilar products, such as evothyroxine capsules and insulin glargine biosimilars, creates sales opportunities related to formulation, packaging, and quality control services tailored for competitive generic and biosimilar markets.

Financial and Market Growth With revenue between $250M and $500M and a funding base of $350M, Lannett demonstrates strong financial health, making it a promising target for supply chain enhancements, contract manufacturing, and quality assurance solutions to support ongoing and new product lines.